Search

Displaying results 2401 - 2410 of 7540 in total
  1. Drug

    Nalidixic acid

    go.drugbank.com/drugs/DB00779
    ApprovedWithdrawn

    Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.

    Synonyms: 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure
  2. Drug

    Viloxazine

    go.drugbank.com/drugs/DB09185
    ApprovedInvestigationalWithdrawn

    In April 2021, an extended-release formulation of viloxazine under the brand name QELBREE was approved by the FDA for the treatment of attention deficit hyperactivity disorder (ADHD).[A247985] … It was first approved in the UK in 1974; however, the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and efficacy.

  3. Drug

    Apremilast

    go.drugbank.com/drugs/DB05676
    ApprovedInvestigational

    It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. … Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases.

    Synonyms: N-{2-[(1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide
  4. Drug

    Narsoplimab

    go.drugbank.com/drugs/DB16418
    ApprovedInvestigational

    [A241045, A241050] Approved by the FDA on December 24, 2025, narsoplimab-wuug is indicated for the treatment of hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in adults … [A241030] Evidence increasingly points to a role for the complement system in TMA.

  5. Drug

    Dextroamphetamine

    go.drugbank.com/drugs/DB01576
    ApprovedIllicitInvestigational

    Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.[L6010,L52145]

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Eladocagene exuparvovec

    go.drugbank.com/drugs/DB16780
    ApprovedInvestigational

    By promoting the expression of AADC, eladocagene exuparvovec leads to the development of motor function in patients with AADC deficiency. … [A253687] It was subsequently approved by the FDA in November 2024.[L51898,L51893]

  7. Drug

    Brilliant blue G

    go.drugbank.com/drugs/DB15594
    Approved

    It was approved by the FDA for ophthalmic use on December 20, 2019.[L10830] … [A188841,A188844] This membrane is thin and translucent, making it difficult to identify during eye surgeries that require high levels of visual accuracy.

  8. Drug

    Baricitinib

    go.drugbank.com/drugs/DB11817
    ApprovedInvestigational

    [L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018. … By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.

  9. Drug

    Phleum pratense pollen

    go.drugbank.com/drugs/DB10394
    ApprovedInvestigational

    Phleum pratense pollen allergenic extract is used in allergenic testing.

    Mixtures: Mixture of Standardized and Non-Standardized Inland Grasses, Mixture of Standardized and Non-Standardized Coastal Grasses
  10. Drug

    Botulinum toxin type A

    go.drugbank.com/drugs/DB00083
    ApprovedInvestigational

    In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use.